Abacavir Sulfate/Lamivudine

硫酸阿巴卡韦/拉米夫定

Report date: 2023/04/25 11:29:34

Base Information

Drug NameAbacavir Sulfate/Lamivudine
Drug Alias NameLamivudine and abacavir阿巴卡韦拉米夫定阿巴卡韦+拉米夫定Abacavir sulfate - lamivudineAbacavir and Lamivudine +[10] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionReverse transcriptase inhibitors
TargetsReverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2004/08/02
Country/TerritoryBelgiumCanadaPanama +[22] 
CombinationsYes LamivudineAbacavir Sulfate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesViiv Healthcare
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcViiv Healthcare BvViiv Healthcare +[4] 
Inactive CompaniesNational Cancer InstituteNational Institute Of Allergy And Infectious Diseases (Niaid)Viiv Healthcare Co
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AR02
Related LinksKEGG